EUVIMEDEUVIMED entdecken
Crossref

Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma

Hazim S Ababneh iD, Andrea K Ng, Jeremy S Abramson, Jacob D Soumerai, Ronald W Takvorian, Matthew J Frigault, Chirayu G Patel

Hematological Oncology · 2024

DOI: 10.1002/hon.3231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2024. Verfasst von Hazim S Ababneh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment for patients with relapsed/refractory large B‐cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET/CT) parameters on the CAR T‐related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre‐ and post‐CAR T metabolic parameters on survival and toxicities following CAR T‐cell therapy. Fifty‐nine patients with PET/CT scans done pre‐and post‐CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19‐targeted CAR T‐cell therapy. The median follow‐up was 10.7 months [interquartile range (IQR): 2.6–25.5 months]. The overall response (complete response‐CR and partial response) and CR rates post‐CAR T were 76% ( n = 45) and 53% ( n = 31), respectively. On univariate analysis, low pre‐CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post‐CAR T (OR = 4.7, p = 0.01, OR = 9.5, p = 0.03, respectively) and CR post‐CAR T (OR = 12.4, p = 0.0004, OR = 10.9, p = 0.0001, respectively). High TLG pre‐CAR T was correlated with cytokine release syndrome (CRS, OR = 3.25, p = 0.04). High MTV pre‐CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR = 4.3, p = 0.01), and high SUV pre‐CAR T was associated with grade 3–4 neurological events (OR = 12, p = 0.01). High MTV/TLG/SUVmax post‐CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre‐CAR T (HR = 2.4, p = 0.03), age ≥60 (HR = 2.7, p = 0.03), and bulky disease (≥5 cm) at the time of apheresis (HR = 2.5, p = 0.02) were identified to be independent prognostic factors for inferior PFS. High MTV post‐CAR T was identified as the most prognostic factor associated with inferior OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansPositron Emission Tomography Computed TomographyRadiopharmaceuticalsImmunotherapy, AdoptiveRetrospective StudiesFluorodeoxyglucose F18PrognosisCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR T-cell therapyPET parametersR/R LBCL

Substanzen

Receptors, Chimeric AntigenRadiopharmaceuticalsFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Hazim S Ababneh

Zitieren

APA

Ababneh, H. S., Ng, A. K., Abramson, J. S., Soumerai, J. D., Takvorian, R. W., Frigault, M. J., & Patel, C. G. (2024). Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.3231

Vancouver

Ababneh HS, Ng AK, Abramson JS, Soumerai JD, Takvorian RW, Frigault MJ, et al. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma. Hematological Oncology. 2024. doi:10.1002/hon.3231

BibTeX
@article{Ababneh2024,
  author = {Ababneh, Hazim S and Ng, Andrea K and Abramson, Jeremy S and Soumerai, Jacob D and Takvorian, Ronald W and Frigault, Matthew J and Patel, Chirayu G},
  title = {Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3231}
}
Kostenlos starten →